[{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Lobsor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Lobsor Pharmaceuticals \/ STADA"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Not Applicable"},{"orgOrder":0,"company":"Synagile","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance Medical System \/ Erik Selin"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D1\/D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Synagile","sponsor":"Clintrex Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Clintrex Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Clintrex Research Corporation"},{"orgOrder":0,"company":"Dizlin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dizlin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizlin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Dizlin Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeuroDerm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Not Applicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"NeuroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ NeuroDerm","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ NeuroDerm"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Carbidopa
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
